Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Wedbush increased their FY2021 earnings estimates for shares of Aimmune Therapeutics in a note issued to investors on Tuesday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings per share of $2.90 for the year, up from their previous estimate of $2.65. Wedbush has a “Outperform” rating and a $42.00 price objective on the stock.
Several other equities research analysts have also commented on AIMT. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $33.00.
TRADEMARK VIOLATION WARNING: “Wedbush Comments on Aimmune Therapeutics, Inc.’s FY2021 Earnings (AIMT)” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/06/wedbush-comments-on-aimmune-therapeutics-inc-s-fy2021-earnings-aimt-updated.html.
Shares of Aimmune Therapeutics (NASDAQ AIMT) traded up 1.29% during trading on Wednesday, reaching $21.93. The company had a trading volume of 287,210 shares. The company’s market capitalization is $1.10 billion. The stock’s 50-day moving average price is $19.91 and its 200-day moving average price is $19.92. Aimmune Therapeutics has a 52 week low of $11.52 and a 52 week high of $27.31.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05.
In related news, CFO Eric Bjerkholt bought 5,000 shares of the stock in a transaction dated Friday, May 12th. The shares were acquired at an average cost of $19.84 per share, for a total transaction of $99,200.00. Following the acquisition, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $99,200. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total value of $134,420.00. Following the transaction, the insider now owns 960 shares in the company, valued at $21,120. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 138,570 shares of company stock worth $2,870,182. Insiders own 24.56% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after buying an additional 2,004,023 shares in the last quarter. Palo Alto Investors LLC boosted its position in shares of Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after buying an additional 513,803 shares in the last quarter. Eventide Asset Management LLC bought a new position in shares of Aimmune Therapeutics during the first quarter valued at $6,736,000. Finally, State Street Corp boosted its position in shares of Aimmune Therapeutics by 49.1% in the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after buying an additional 282,744 shares in the last quarter. Institutional investors and hedge funds own 69.62% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
